Medtronic plc stock (IE00BTN1Y115): Global leader in medical technology

Medtronic plc maintains its position as one of the world's largest medical technology companies, focusing on therapies that address chronic diseases. The firm reported fiscal 2026 second-quarter results on February 18, 2026, with worldwide revenue of $8.4 billion, up 4.4 percent as reported and 5.6 percent adjusted, according to Medtronic press release as of 02/18/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Medtronic plc: core business model

Medtronic plc develops, manufactures, and sells a wide range of medical devices and therapies. Its portfolio includes pacemakers, insulin pumps, spinal cord stimulators, and surgical tools. The company operates through four main segments: Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio, and Diabetes. This diversified approach allows Medtronic to serve hospitals, clinics, and patients globally, with a strong emphasis on minimally invasive procedures.

Founded in 1949 and headquartered in Dublin, Ireland, Medtronic generates the majority of its revenue from the United States. The firm invests heavily in research and development, spending about 9 percent of revenue on R&D annually, as noted in its fiscal 2025 annual report published August 2025, according to Medtronic IR as of 08/2025. This supports a pipeline of over 1,000 clinical trials.

Main revenue and product drivers for Medtronic plc

The Cardiovascular Portfolio is Medtronic's largest revenue contributor, accounting for roughly 35 percent of total sales. Key products include the Micra leadless pacemaker and the Evolut transcatheter aortic valve replacement system. In Q2 fiscal 2026, this segment grew 5.1 percent adjusted, driven by structural heart and coronary therapies, per the February 18, 2026 earnings release.

Diabetes revenue comes from continuous glucose monitoring systems and insulin delivery devices like the MiniMed 780G. This segment saw 10.7 percent adjusted growth in the same quarter, fueled by strong US demand. Neuroscience products, including deep brain stimulation for Parkinson's, and the Medical Surgical Portfolio with endoscopic tools, round out the drivers. US market exposure remains critical for US investors, as it represents over 50 percent of revenue.

Industry trends and competitive position

The medical device industry faces trends like digital health integration, robotics in surgery, and personalized medicine. Medtronic leads in cardiac rhythm management with about 45 percent US market share for pacemakers, according to IDC Health as of 01/2026. Competitors include Abbott Laboratories, Boston Scientific, and Intuitive Surgical.

Medtronic's scale—$32.4 billion in fiscal 2025 revenue—provides advantages in regulatory approvals and global distribution. Recent FDA approvals for the Hugo robotic-assisted surgery system in 2025 position it against Intuitive Surgical's da Vinci platform.

Why Medtronic plc matters for US investors

Listed on the NYSE under ticker MDT, Medtronic offers US investors exposure to the $500 billion global medtech market, with heavy reliance on the US healthcare system. Medicare reimbursement policies directly impact its cardiac and diabetes segments. The stock traded at $82.50 USD on 05/13/2026 on NYSE, according to Yahoo Finance as of 05/13/2026.

Conclusion

Medtronic plc sustains growth through innovation in high-demand areas like cardiovascular and diabetes care. Recent quarterly results show steady revenue expansion amid competitive pressures. US investors monitor its execution in robotics and digital health for long-term positioning in the evolving medtech landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.